Flatulence News and Research

RSS

Flatulence is the expulsion through the rectum of a mixture of gases that are byproducts of the digestion process of mammals and other animals.

FDA approves Creon (pancrelipase) - designed to help those with cystic fibrosis

The U.S. Food and Drug Administration announced that it has approved Creon (pancrelipase), a pancreatic enzyme replacement product designed to help patients with cystic fibrosis and others with exocrine pancreatic insufficiency (EPI) digest and absorb nutrients from foods.

7 May 2009

Vaccine for Coeliac disease could mean the end of gluten free diets

Australian scientists have developed an experimental vaccine to treat coeliac disease. The team at the Walter and Eliza Hall (WEHI) Institute in Melbourne are hoping a phase 1 clinical trial of the vaccine, due to begin this month, will eventually lead to an effective clinical treatment for the disease.

15 Apr 2009

Garden peas may help fight high blood pressure, kidney disease

Researchers in Canada are reporting that proteins found in a common garden pea show promise as a natural food additive or new dietary supplement for fighting high blood pressure and chronic kidney disease (CKD).

22 Mar 2009

FDA approves Entereg (alvimopan) to restore bowel function

The U.S. Food and Drug Administration approved Entereg (alvimopan) today to accelerate the restoration of normal bowel function in patients 18 years and up who have undergone partial large or small bowel resection surgery. Entereg will be used in hospitalized patients who can receive no more than 15 doses.

20 May 2008

Tredaptive and Janumet recommended for approval in European Union

Food and Drug Administration (FDA) is currently reviewing the combination of extended release (ER) niacin and laropiprant under the trademark Cordaptive (ER niacin/laropiprant). The CHMP recommendation does not apply to regulatory decisions by the FDA and no inferences should be made about pending FDA regulatory actions based on the recommendation of the CHMP.

24 Apr 2008

GlaxoSmithKline obtains U.S. OTC marketing rights to MEVACOR (lovastatin) from Merck

GlaxoSmithKline, Philadelphia, PA, USA (GSK) and Merck & Co., Inc., Whitehouse Station, NJ, USA (Merck), announced today that they have entered into an agreement for over-the-counter (OTC) marketing rights for MEVACOR (lovastatin).

27 Nov 2007

New analyses of long-term LIALDA (mesalamine) data presented at ACG

Post-hoc and other analyses of secondary endpoints of a long-term safety and tolerability study of Shire plc's ulcerative colitis (UC) drug LIALDA (mesalamine) provide further data on LIALDA in patients with mild to moderate ulcerative colitis.

16 Oct 2007

FDA accepts Sucampo's sNDA for Lubiprostone for the treatment of irritable bowel syndrome

Sucampo Pharmaceuticals, Inc., has announced that the supplemental New Drug Application (sNDA) for lubiprostone (8 mcg, oral gel capsules, twice daily) for the treatment of irritable bowel syndrome with constipation (IBS-C) has been accepted for review by the U.S. Food and Drug Administration (FDA).

18 Sep 2007

Tips and fact for belching, bloating, and flatulence

We've all experienced intestinal gas, some more than others.

18 Jul 2007

NDA for Lubiprostone to treat irritable bowel syndrome with constipation

Sucampo Pharmaceuticals, Inc., has announced that it has submitted a supplemental New Drug Application to the U.S. Food and Drug Administration to seek market approval of a lower strength of lubiprostone (8 mcg) to treat irritable bowel syndrome with constipation (IBS-C).

13 Jul 2007

Eurand files NDA for Zentase for the treatment of exocrine pancreatic insufficiency

Eurand has announced that Eurand Pharmaceuticals Ltd. initiated the rolling submission of its new drug application (NDA) with the U.S. Food and Drug Administration (FDA) for Zentase for the treatment of Exocrine Pancreatic Insufficiency (EPI). Zentase (formerly EUR-1008), the company's lead product candidate, has been granted fast-track designation by the FDA.

14 Jun 2007

Lubiprostone may improve symptom relief rates in adults with irritable bowel syndrome with constipation

A new study demonstrated that the active ingredient in AMITIZA (lubiprostone), given 8 mcg twice a day, may improve symptom relief rates in adults with irritable bowel syndrome with constipation (IBS-C).

22 May 2007

Children with lactose intolerance still need dairy's nutrients

The American Academy of Pediatrics (AAP) is recommending in a new report that children with lactose intolerance should include dairy foods as part of a healthy diet in order to get enough calcium, vitamin D, protein and other nutrients essential for bone health and overall growth.

6 Sep 2006

New drug will treat those winter blues

The U.S. Food and Drug Administration (FDA) has given it's approval for a drug to treat a condition known as Seasonal Affective Disorder (SAD).

14 Jun 2006

Chantix new quit smoking drug approved

The U.S. Food and Drug Administration (FDA) has given approval for the sale of the first smoking cessation drug in almost ten years.

11 May 2006

Rifaximin effective in treating flatulence and irritable bowel syndrome

In the first study of its kind, researchers discovered that rifaximin, an antibiotic used to treat diarrhea, is an effective treatment for abdominal bloating and flatulence, including in irritable bowel syndrome (IBS) patients.

16 Feb 2006

Data establishes safety profile of new GlaxoSmithKline rotavirus vaccine candidate

Data from one of the largest infant vaccine trials ever conducted, published in the New England Journal of Medicine (NEJM), showed GlaxoSmithKline's (GSK) rotavirus vaccine candidate as effective against rotavirus disease (rotavirus gastroenteritis) in the first year of life. Rotavirus is the leading recognized cause of diarrhea-related illness and death among infants and young children.

6 Jan 2006

Episiotomy does not reduce the risk of injury to infants during a complicated birth

A new study from Johns Hopkins suggests that routine widening of the vagina, a procedure known as an episiotomy, does not reduce the risk of injury to infants during a complicated birth, such as when a baby's shoulders are stuck in the birth canal after the head is already out.

4 Oct 2004